Equities analysts expect Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to post sales of $876.57 million for the current quarter, according to Zacks. Nine analysts have issued estimates for Alexion Pharmaceuticals’ earnings. The lowest sales estimate is $847.72 million and the highest is $900.89 million. Alexion Pharmaceuticals posted sales of $831.00 million during the same quarter last year, which suggests a positive year-over-year growth rate of 5.5%. The business is expected to announce its next earnings results on Thursday, February 15th.

On average, analysts expect that Alexion Pharmaceuticals will report full-year sales of $876.57 million for the current fiscal year, with estimates ranging from $3.49 billion to $3.54 billion. For the next year, analysts forecast that the firm will report sales of $4.07 billion per share, with estimates ranging from $3.91 billion to $4.28 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Alexion Pharmaceuticals.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The business had revenue of $859.00 million during the quarter, compared to analyst estimates of $864.34 million. During the same period in the previous year, the business posted $1.23 EPS. The company’s quarterly revenue was up 7.5% on a year-over-year basis.

Several research analysts have recently commented on ALXN shares. BidaskClub raised shares of Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, August 20th. J P Morgan Chase & Co raised shares of Alexion Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $163.00 to $175.00 in a report on Tuesday, September 5th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $173.00 price target (up from $168.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. SunTrust Banks reaffirmed a “buy” rating and issued a $180.00 price target (up from $170.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. Finally, Leerink Swann reissued an “outperform” rating and set a $182.00 target price (up from $170.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. They noted that the move was a valuation call. Four equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $155.47.

Alexion Pharmaceuticals (NASDAQ ALXN) traded up $2.67 during midday trading on Tuesday, hitting $115.76. 2,850,201 shares of the stock traded hands, compared to its average volume of 2,299,953. Alexion Pharmaceuticals has a 1-year low of $96.18 and a 1-year high of $149.34. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51. The firm has a market cap of $25,365.93, a price-to-earnings ratio of 23.22, a PEG ratio of 1.23 and a beta of 1.18.

Large investors have recently modified their holdings of the company. Commerzbank Aktiengesellschaft FI lifted its stake in shares of Alexion Pharmaceuticals by 151.5% in the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 132,698 shares of the biopharmaceutical company’s stock worth $16,145,000 after acquiring an additional 79,943 shares during the period. Jennison Associates LLC lifted its stake in shares of Alexion Pharmaceuticals by 720.0% in the 3rd quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock worth $748,116,000 after acquiring an additional 4,682,336 shares during the period. HPM Partners LLC lifted its stake in shares of Alexion Pharmaceuticals by 267.2% in the 2nd quarter. HPM Partners LLC now owns 6,680 shares of the biopharmaceutical company’s stock worth $656,000 after acquiring an additional 4,861 shares during the period. Assenagon Asset Management S.A. lifted its stake in shares of Alexion Pharmaceuticals by 4,509.0% in the 3rd quarter. Assenagon Asset Management S.A. now owns 884,150 shares of the biopharmaceutical company’s stock worth $124,037,000 after acquiring an additional 864,967 shares during the period. Finally, Principal Financial Group Inc. lifted its stake in shares of Alexion Pharmaceuticals by 1.2% in the 2nd quarter. Principal Financial Group Inc. now owns 335,525 shares of the biopharmaceutical company’s stock worth $40,823,000 after acquiring an additional 4,115 shares during the period. 94.33% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/876-57-million-in-sales-expected-for-alexion-pharmaceuticals-inc-alxn-this-quarter/1766844.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Get a free copy of the Zacks research report on Alexion Pharmaceuticals (ALXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.